Feature|Articles|October 13, 2026

Rising PSA After Prostate Cancer Treatment: What Happens Next?

Fact checked by: CURE staff

A rising PSA after surgery or radiation can be frightening. Learn what biochemical recurrence means, which tests come next and your treatment options.

For many men, the first good PSA test after prostate cancer treatment is a huge relief. When a later result starts to creep up, that relief can quickly turn to worry.

A rising PSA does not automatically mean the cancer has spread. In many cases, it means the cancer was caught very early, often before it shows up on any scan, while treatment can still make a difference.

Here is what a rising PSA after treatment means, what tests usually come next and how doctors decide what to do.

What does a rising PSA mean after prostate cancer treatment?

PSA (prostate-specific antigen) is a protein made by prostate cells, both healthy and cancerous. After surgery to remove the prostate, PSA should fall to a level so low that the test can’t detect it.

“For patients who have already been treated with surgery, their PSA goes to zero and becomes undetectable. Once the PSA is undetectable, it becomes a very good surrogate for disease recurrence,” Dr. Manuel Ozambela Jr., a urologic surgical oncologist at Baptist Health Herbert Wertheim Cancer Institute, previously told CURE.

If PSA becomes detectable and keeps rising, prostate cancer cells may still be in the body. Doctors call this biochemical recurrence, which means the cancer is found through a blood test before it appears on imaging or causes symptoms.

What PSA level counts as biochemical recurrence?

The cutoff depends on the first treatment:

After surgery (radical prostatectomy): A PSA of 0.2 ng/mL or higher is considered biochemical recurrence, according to the American Urological Association (AUA) and the National Cancer Institute. Doctors usually confirm it with a second test.
After radiation: The prostate is still in place, so PSA usually doesn’t drop to zero. Doctors generally look for a rise of 2 ng/mL above the lowest level PSA reached after treatment.

“As long as the PSA stays below 0.2, or remains undetectable, we’re very confident the patient has no evidence of disease,” Ozambela said. “If that PSA starts to climb, then we worry about what’s called biochemical recurrence, meaning the PSA is telling us that the cancer may be back already.”

One higher number is a reason to look more closely, but it is not a reason to panic. Your doctor will watch the trend over several tests.

Why does it matter how fast PSA is rising?

Doctors look at how high PSA is and also how quickly it is climbing. This is often measured as PSA doubling time, the number of months it takes PSA to double.

According to the American Cancer Society, how fast PSA rises and the original Gleason score can help predict how soon the cancer might spread. AUA guidelines treat a PSA doubling time of six months or less, a PSA of 0.7 ng/mL or higher, or high-grade disease (grade group 4 or 5) as higher-risk features. These can change which treatment a doctor recommends.

What tests come after a rising PSA?

The next step is usually imaging to find where the cancer is. More and more often, that means a PSMA PET scan.

PSMA is a protein found on most prostate cancer cells. A PSMA PET scan uses a small amount of a tracer that attaches to PSMA, so areas of cancer light up on the scan. AUA guidelines say doctors may use PSMA PET instead of conventional imaging, and they recommend this newer type of PET scan for men who are considering salvage radiation.

Scans help answer the key question: Is the cancer still near the prostate, in nearby lymph nodes or in other parts of the body?

Dr. Brian Keith McNeil, vice chair of the Department of Urology at SUNY Downstate Health Sciences University, encourages patients to know their initial PSA level and Gleason score and to ask their doctor, “What is my risk category?” and “Would a PSMA-PET scan be helpful for me at this time?”

What are the treatment options for biochemical recurrence?

The right plan depends on your first treatment, your PSA numbers and what the scans show.

Salvage radiation after surgery: If PSA rises after surgery, radiation to the area where the prostate was can still be curative. AUA guidelines recommend offering it while PSA is 0.5 ng/mL or lower, because earlier tends to be better.
Adding hormone therapy: For men with higher-risk features, guidelines recommend adding hormone therapy (androgen deprivation therapy, or ADT) to salvage radiation, usually for four to six months and sometimes for 18 to 24 months.
Treatment after radiation: If PSA rises after radiation, surgery or ablation (treatments that destroy tissue with heat or cold) may be possible, but these carry a higher risk of side effects such as incontinence.
Xtandi for high-risk recurrence: In November 2023, the FDA approved Xtandi (enzalutamide) for men whose cancer has not spread but whose PSA is doubling every nine months or faster. In the EMBARK trial of 1,068 men, Xtandi plus the hormone therapy leuprolide lowered the risk of the cancer spreading or death by 58% compared with leuprolide alone. Xtandi alone lowered that risk by 37%. Common side effects included hot flashes, muscle and joint pain, fatigue, falls and bleeding.
Close monitoring: Prostate cancer often grows slowly. For some men, especially those with a slowly rising PSA, watching carefully may be a reasonable choice at first.

What new prostate cancer treatments are being studied?

Research continues for men whose cancer spreads and stops responding to hormone therapy. On Oct. 8, the FDA granted fast track designation to VIR-5500, an investigational therapy for late-stage metastatic castration-resistant prostate cancer. Fast track helps speed development of promising drugs for serious conditions.

VIR-5500 attaches to both PSMA on cancer cells and to immune cells called T cells, bringing them together so the immune system can attack the cancer. In an early phase 1 study, PSA dropped by at least half in 82% of 17 men who received higher doses. Cytokine release syndrome, an immune reaction that can cause fever, occurred in 50% of people in the study and was mostly mild. The study is still small and early, and larger phase 3 trials are expected in 2027.

What should I ask my doctor about a rising PSA?

What is my PSA doubling time?
Should I get a PSMA PET scan?
Is salvage radiation an option for me, and when should I start?
Would adding hormone therapy help in my situation?
Am I a candidate for Xtandi or a clinical trial?
What side effects should I expect, and how can they be managed?

A rising PSA can feel like starting over. But the same test that raises the alarm is also one of the best tools doctors have for guiding what comes next.

“The PSA is probably the best biomarker in oncology because it’s so good at telling us response to treatment in patients with prostate cancer,” Ozambela said.

Because PSA testing is so sensitive, many men find out about recurrence early, when there is still time to make careful decisions with their care team. To learn how PSA is tracked from diagnosis on, read Why PSA Monitoring Matters After a Prostate Cancer Diagnosis.